Eugia warning letter resolution uncertainty
Despite procedural observations, the USFDA decision on the warning letter is pending; management is cautiously optimistic but cannot predict outcome.
AUROPHARMA / Q3-FY26 / risks
Keep the risk register visible.
Aurobindo Pharma · Material risks, their source context, and severity in the latest available quarter.
Research layer active
ConCallIQ research layer
Signal, with the source still visible.
Use the controls below to narrow the view, then follow the evidence into the next layer of context.
Risk intelligence
Material risks this quarter
high
6-APA predatory pricing impact
6-APA prices have been below cost of manufacture internationally, causing losses; correction expected by April but timing uncertain.
Lannett acquisition regulatory delays
FTC approval process is ongoing; any delay or unexpected conditions could impact the timeline and synergies.
Ramp-up costs from multiple greenfield projects
EBITDA burn from ramping up facilities like Pen G, Dayton, Raleigh, and biosimilars may pressure near-term margins.